Almost all of it is converted into 6-mercaptopurine in the body to work. Because of its slow conversion process, it works slowly. It can inhibit Friend leukemia, inhibit virus infection in mice, inhibit spleen enlargement, and reduce the virus titer in the spleen and plasma. Rats injected with this product intraperitoneally for 4 to 5 months have weight loss, severe anemia and increased reticulocytes. Rabbits given this drug in early pregnancy can cause teratogenesis, mainly affecting limb development. It can have an immunosuppressive effect by interfering with RNA metabolism. If a small dose exists in the culture medium for a long time, it can inhibit the killing cell effect of sensitized lymphocytes in vitro.

This product belongs to Class III antiarrhythmic drugs. The main electrophysiological effect is to prolong the action potential and effective refractory period of various myocardial tissues, which is conducive to eliminating reentrant excitation. At the same time, it has mild non-competitive α and β adrenergic receptor blocking and mild Class I and IV antiarrhythmic properties. Reduce the automaticity of the sinus node. It has no effect on the resting membrane potential and action potential height. The inhibition of forward conduction of the atrioventricular bypass pathway is greater than the reverse. Due to excessive prolongation of repolarization, the electrocardiogram has QT interval prolongation and T wave changes after oral administration, which can slow down the heart rate by 15~20% and prolong the PR and Q-T intervals by about 10%. It has a direct dilation effect on the coronary arteries and peripheral blood vessels. It can affect thyroid hormone metabolism. The characteristics of this product are long half-life, so the number of medications is small, the therapeutic index is large, and the antiarrhythmic spectrum is wide.

Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase. It reduces plasma cholesterol and serum lipoprotein concentrations by inhibiting HMG-CoA reductase and cholesterol biosynthesis in the liver, and enhances LDL uptake and metabolism by increasing LDL receptors on the surface of liver cells. Atorvastatin reduces LDL cholesterol production and the number of LDL cholesterol particles, leading to a significant and persistent increase in LDL cholesterol receptor activity, and thus beneficial changes in the mass of circulating LDL cholesterol particles. Atorvastatin can effectively reduce LDL cholesterol levels in patients with homozygous familial hypercholesterolemia.

A selective and competitive inhibitor of HMG-CoA reductase, it can reduce plasma cholesterol and lipoprotein levels by reducing cholesterol synthesis and increasing the number of LDL receptors, thereby reducing the risk of atherosclerosis, while also regulating high-density lipoprotein cholesterol levels.

Extracting pharmacological effects from the above information